Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regularly issues news on its medicines, clinical programs and corporate developments across multiple therapeutic areas. As a biotechnology company focused on serious diseases, Regeneron’s announcements often cover advances in eye care, allergic and inflammatory diseases, oncology, hematology, cardiovascular disease, infectious disease and rare conditions.
News about Regeneron frequently highlights regulatory milestones for its marketed products. Recent examples include approvals for Dupixent (dupilumab) in additional indications and age groups, such as chronic spontaneous urticaria in the European Union and bronchial asthma in children in Japan, as well as expanded indications and dosing flexibility for EYLEA HD (aflibercept) Injection 8 mg in retinal diseases. The company also reports on new approvals for Libtayo (cemiplimab), including adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union.
Investors and healthcare professionals can expect updates on Regeneron’s oncology and hematology pipeline, including data from trials of Lynozyfic (linvoseltamab) in multiple myeloma and odronextamab in B‑cell non‑Hodgkin lymphomas, as well as programs in paroxysmal nocturnal hemoglobinuria and severe aplastic anemia. Regeneron often presents such data at major medical meetings, and issues press releases summarizing efficacy and safety results.
Corporate and R&D collaboration news is another recurring theme. The company has announced partnerships such as its global collaboration with Tessera Therapeutics on TSRA‑196, an investigational in vivo gene editing therapy for alpha‑1 antitrypsin deficiency, and provides updates on its factor XI antibody program for anticoagulation. Regeneron also communicates scheduling of quarterly and annual financial results webcasts and investor events, including its ‘Regeneron Roundtable’ series.
This news page aggregates these types of updates so readers can follow product approvals, late-stage trial readouts, scientific presentations, strategic collaborations and financial reporting dates related to REGN. For ongoing research and investment analysis, checking this feed regularly can provide timely insight into Regeneron’s progress across its broad portfolio.
Viz.ai has announced a multi-year partnership with Sanofi (SNY) and Regeneron (REGN) to develop and evaluate an AI-powered workflow solution for Chronic Obstructive Pulmonary Disease (COPD). The collaboration will focus on deploying the Viz COPD module, which uses electronic health record (EHR) data and artificial intelligence to improve detection and management of high-risk COPD patients.
The solution will be implemented across Viz.ai's network of over 1,700 hospitals and health systems, reaching more than 60,000 healthcare providers. COPD, affecting an estimated 392 million people globally and ranking as the fourth leading cause of death worldwide, remains underprioritized and undertreated. The AI-powered system will screen and triage patients using natural language processing, aligning with established clinical guidelines to identify high-risk individuals requiring follow-up care.
At the 75th Regeneron International Science and Engineering Fair (ISEF), nearly 1,700 young scientists from 48 U.S. states and 60+ countries competed for over $9 million in awards. The top prize, the $100,000 George D. Yancopoulos Innovator Award, went to Adam Kovalčík from Slovakia for developing a more efficient and cost-effective method to produce the antiviral drug galidesivir, reducing production costs from $75/gram to $12.50/gram.
Other major winners included Benjamin Davis ($75,000) for a desktop plastic recycling system, Siyaa Poddar ($75,000) for toxic dust detection technology, and a team of three students ($50,000) for developing a brain-controlled bionic prosthetic leg. The competition, sponsored by Regeneron Pharmaceuticals (NASDAQ: REGN), celebrated its milestone 75th year of fostering STEM innovation and has provided STEM experiences to over 3.2 million students since 2020.
- New data from the Phase 3 C-POST trial evaluating Libtayo in post-surgical high-risk cutaneous squamous cell carcinoma (CSCC)
- Initial results from LINKER-MM2 trial exploring combinations of linvoseltamab (BCMAxCD3 bispecific antibody) with carfilzomib or bortezomib in relapsed/refractory multiple myeloma
The presentations will cover multiple cancer types including non-melanoma and melanoma skin cancer, lung cancer, lymphoma, and multiple myeloma. Notable updates include results from a Phase 2 trial of vidutolimod combined with anti-PD-1 therapy in melanoma. The FDA is currently reviewing Biologics License Applications for linvoseltamab and odronextamab, with target action dates of July 10 and July 30, 2025, respectively.
Regeneron reported Q1 2025 financial results with total revenues of $3.0 billion, showing mixed performance across its product portfolio. Dupixent global sales grew 19% to $3.67 billion, while EYLEA HD U.S. sales increased 54% to $307 million.
Key highlights include:
- FDA approval of Dupixent for chronic spontaneous urticaria
- Japanese approval for Dupixent in COPD treatment
- EU approval of Lynozyfic for multiple myeloma
- Priority review status for EYLEA HD in retinal vein occlusion
The company announced over $7 billion in planned investments for New York and North Carolina infrastructure. Financial metrics showed GAAP diluted EPS of $7.27 and non-GAAP EPS of $8.22. While total EYLEA franchise sales declined 26% to $1.04 billion, the company maintains a robust pipeline with approximately 45 product candidates in clinical development.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
